Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boehringer Ingelheim sees improved performance in first half of 2015

Boehringer Ingelheim sees improved performance in first half of 2015

5th August 2015

Boehringer Ingelheim has announced its financial results for the first six months of 2015, during which it recorded slight year-on-year growth.

Net sales in the first half of 2015 increased by about two percent year on year to 7.4 billion euros (5.16 billion pounds). In euro terms, the growth rate was 13 percent, thanks to the euro's recent weakness in currency conversions.

The firm's consumer healthcare and animal health businesses performed particularly well, while its prescription medicines business remained stable. Key regulatory approvals were secured for products such as Giotrif, Vargatef, Synjardy and Glyxambi.

For the full year, the company is still forecasting moderate currency-adjusted single-digit growth in net sales.

Professor Andreas Barner, chairman of the board of managing directors at Boehringer Ingelheim, said: "In the past few months, we have pushed ahead with updating our portfolio with our market launches, thereby not only creating growth potential but also taking advantage of it."ADNFCR-8000103-ID-801796608-ADNFCR

We currently have 10 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.